PacBio (PACB) announced a strategic collaboration to implement PacBio HiFi whole genome sequencing, WGS, as part of a newborn screening research program. This marks the first initiative in Asia Pacific to explore the use of PacBio’s HiFi sequencing technology at population scale – an effort designed to evaluate how comprehensive genomic data can support earlier, more accurate identification of rare and treatable conditions in newborns. The collaboration highlights Thailand’s growing leadership in precision medicine and offers a potential model for countries seeking to modernize newborn screening with genome-wide approaches.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PACB:
- Largest borrow rate increases among liquid names
- PacBio announces plans to improve methylation detection in HiFi Chemistry
- PacBio to be technology partner to DAC’s NADR project
- Cathie Wood’s ARK Investment bought 143.5K shares of PacBio today
- PacBio price target lowered to $1.50 from $2 at Bernstein